PHAXIAM Therapeutics SA

PHXM

Company Profile

  • Business description

    PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.

  • Contact

    60 Avenue Rockefeller
    Lyon69008
    FRA

    T: +33 478744438

    E: [email protected]

    https://www.phaxiam.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    49

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.2090.501.08%
CAC 407,770.48176.612.33%
DAX 4023,086.65589.672.62%
Dow JONES (US)41,317.43564.471.39%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,977.73266.991.51%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,327.89179.291.48%
S&P 5005,686.6782.531.47%
S&P/ASX 2008,238.0092.401.13%
SSE Composite Index3,279.037.62-0.23%

Market Movers